Navigation Links
"Decryption" of Enzyme's Functions Paves Way for Future Drug Discovery

Scientists have achieved the first success in "decrypting" an enzyme's function from its structure, a breakthrough that may open an efficient route to drug discovery.

Led by UCSF's Brian Shoichet, Steven Almo of the Albert Einstein College of Medicine, and Frank Raushel of Texas A and M, the study offers a solution to the puzzle that hinders drug discovery, as many of the most successful drugs work by blocking enzyme action.

Shoichet says if the new strategy works with other enzymes, it should become a potent tool to determine how key enzymes work in the body.

The researchers achieved this success by modifying a technique called molecular docking, a computer-aided modeling strategy used to search for potential drugs.

Docking works by allowing researchers to first determine the atom-by-atom structure of an enzyme and then screen many thousands of molecules for one that fits into the empty "active site" of the enzyme.

According to Shoichet, a molecule that fits the enzyme's active site will block its activity, just what many promising drugs do.

The researchers say that the key to their success was a computational feat: simulating candidate substrates that mimicked unstable "intermediate" molecules - those that exist only briefly as the catalyst turns the substrate into a new molecule.

"To tell the truth, we were very surprised that the docking approach worked to determine the substrate. There's so many ways that the approach can go wrong. We're all very gratified," Nature magazine quoted Shoichet as saying.

During the study, the researchers extracted an enzyme from a bacterium known as Thermotoga maritima, a microbe that normally lives at very high temperatures and pressures near volcanic ocean vents. Its structure was determined as a part of the structural genomics project, a large-scale, worldwide effort to determine the structures of enzymes and re
'"/>




Page: 1 2

Related medicine news :

1. Regular Use Of Cocaine Can Impair Brain Functions
2. Heart Functions Being Redefined By Researchers
3. Anticancer Properties of Vitamin D Could Be Separated From Other Functions
4. A New study Throws Light On The Growth & Functions Of Insulin Producing Beta Cells
5. Triple Therapy Shows Better Improvement of Brain Functions
6. Loss of Functions Traced in Alzheimers disease
7. Ariel Sharon Moved out of ICU After Improvement in Kidney Functions
8. Lung Functions and Stroke
9. Dry Eye Syndrome Affects Visual Functions
10. Life Functions Governed by Circadian Rhythms-new Research
11. Treatment of Bacterial Infection Paves the Way to Treat CF Infection

Post Your Comments:
(Date:11/23/2009)...re/--JustintimefortheThanksgivingcelebration, tur...forcookingupadeliciousmeal:deep-friedturkeyin100%p... turkeyfrying.net alsoprovidesrecipesfromthele...takingtheturkeybeyondThanksgiving.Thenewlylaunched...ryingwith100%peanutoil. ,, "Ienjoyfryingwithpea...
(Date:11/23/2009)...s to treatment advances, study finds , ,...ontent of saliva changes as people age, and better... simple test to diagnose and treat age-related dis...ains numerous proteins that play a role in digesti...hers are trying to find ways to use these proteins...
(Date:11/23/2009)...Health System study has found that one out of five...ly 100 pounds or more overweight. , Researchers ...e 2 diabetes are obese, and 20.7 percent are morbi... 2 diabetes, 1 in 3 is morbidly obese. , "The ra... increasing at a very alarming rate, and this has ...
(Date:11/23/2009)...ave been a simple case for a New York auto acciden... charge. , New York (PRWE...e for New York auto accident attorneys passed to...rage turned fatal., , , , ,According to the New ...s shot and killed during a heated road-rage argume...
(Date:11/23/2009)...re/--ChristineHoehnehasjoined LocktonBenefitGroup ....HoehnewillserveasanAccountExecutiveinLockton,s In...neapolis office. ,, (Logo: http://www.newscom.c...ethrilledtohaveChristinejoinourteam,"saidPamEnrigh...hebroadensourabilitytoassistourmultinationalclient...
Breaking Medicine News(10 mins):Health News:Diabetics show alarming increase in morbid obesity 2Health News:An Incident of Road Rage Turns Into Murder 2Health News:Lockton Benefit Group Expands International Benefit Team 2
... that looks matter for everyone from presidential ...risis is forcing many consumers to re-evaluate the... and plastic surgeon polls are being release in co...tober 31st through November 5th. , "It appears mo...
...f Vertebral Compression Fracture Treatment Using...t, SAN JOSE, Calif., Oct. 28 DFine, Inc., a deve... vertebral compression fractures,(VCFs), has secur...ure Partners and Vanguard Ventures., DFine is ded...
...e Report Card Provides,Information on NY, NJ, RI, ...ty, Payments, LAKE SUCCESS, N.Y., Oct. 28 Health...U.S. have a unique tool for,evaluating the region,...ata on the cost and quality of care received by,me...
...f Universit Laval researchers has shown that the m...re exacerbated in the brains of mice fed a diet ri...the studywhich suggests that diets typical of most...e this, the team led by Frdric Calon used a type o...
...d 2008, HARRISBURG, Pa., Oct. 28 More than 600,P...al Conference of The,National Alliance on Mental I... "Today,s Family and the Faces of Mental Illness: ...open to the,public, will take place Wednesday, Oct...
...etween leading researchers in academia and industr...ds to discovery of method for promoting HEK 293 ce...rom colostrum. , Fort Col...ng the benefit of using recombinant lactoferrin (L...
Other Medicine News:Health News:Consumers and plastic surgeons say economy is cutting into cosmetic procedures 2Health News:DFine Secures $30 Million in Series D Funding 2Health News:Foundation Releases Comprehensive Regional Health Care Report Card 2Health News:Foundation Releases Comprehensive Regional Health Care Report Card 3Health News:Foundation Releases Comprehensive Regional Health Care Report Card 4Health News:A high-fat diet could promote the development of Alzheimer's 2Health News:NAMI Pennsylvania Announces Program for Annual Statewide Conference 2Health News:Global Scientific Research Collaboration Leads to Breakthrough in Culturing HEK 293 Cells in Animal-free Media 2
(Date:11/23/2009)...3/PRNewswire-FirstCall/-- LexiconPharmaceuticals,I...fromitsPhase2clinicalstudywith LX1031 inpatientswi...epresentedatGASTRO2009inLondonthisweek.Resultsfrom...mptoms,willbepresentedbyDr. PhilipM.Brown ,Lexicon...ber25,2009at2:30pmlocaltimeatthesessionentitled,"T...
(Date:11/23/2009)...RNewswire-FirstCall/--WoundManagementTechnologies,...rofspecialtymedicalproducts,announcedthatithasfile...ivemanagementbusinessupdatetoillustratethedevelopm...ncreased33.5%to$102,926vs.Q32008salesof$77,084. ,...27,892vs.Q32008shareholderequityof$(321,257) ,...
(Date:11/23/2009)...,Nov.23/PRNewswire-FirstCall/--Anesiva,Inc.(Nasdaq....U,PrichardhaveagreedtojointheAnesivaboardofdirect...esivaandArcionTherapeutics.Completionofthemergeris...previouslyannouncedAnesiva2009AnnualMeetingofStock...OysterPoint,Suite107A,SouthSanFrancisco,California...
Breaking Medicine Technology:Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 2Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Building Healthier America Announces the High Five Program Addressing Factors Affecting the Energy Levels of Overweight Men 57152 1Building Healthier America Announces the High Five Program Addressing Factors Affecting the Energy Levels of Overweight Men 57152 2Building Healthier America Announces the High Five Program Addressing Factors Affecting the Energy Levels of Overweight Men 57152 3Texas Cardiac Arrhythmia Institute at St Davids Medical Center Orders 4 Odyssey Systems 57150 1Texas Cardiac Arrhythmia Institute at St Davids Medical Center Orders 4 Odyssey Systems 57150 2Texas Cardiac Arrhythmia Institute at St Davids Medical Center Orders 4 Odyssey Systems 57150 3Texas Cardiac Arrhythmia Institute at St Davids Medical Center Orders 4 Odyssey Systems 57150 4Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 1Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 2Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 3Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 4
...r Validate Lipidomic-Based Therapeutics as an Emer...ery, SAN DIEGO, Sept. 4 Lpath, Inc. (OTC Bulleti... agents against bioactive,lipids, reported positiv...,and AMD with Lpathomab(TM), the company,s mouse m...cid). These results confirm the expected potent,an...
...la., Sept. 4 In an extensive analysis of,clinical...rolimus-eluting,Coronary Stent was associated with...need for reintervention compared to the Taxus Sten... This meta-analysis of 16 randomized,clinical tria... kind to,date, is now posted on the Journal of the...
Other Medicine Technology:Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process 2Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process 3Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 2Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 3Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 4
PROXIMATE ILS Circular Sizer Set
VALTRAC™ Reusable Purstring Device
EEA™ Reusable 34 mm Sizer
Calcitonin Assay Immunoradiometric (IRMA) Assay
Medicine Products: